

IX BIOPHARMA LTD.
(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT OF 13,710,000 NEW ORDINARY SHARES IN THE CAPITAL OF IX BIOPHARMA LTD. – ALLOTMENT AND ISSUE OF SUBSCRIPTION SHARES

Unless otherwise defined, capitalised terms herein shall bear the same meanings as in the Company's announcements dated 12 July 2022 and 19 July 2022 in relation to the Proposed Placement (collectively, the "**Announcements**").

Further to the Announcements, the Directors are pleased to announce that 13,710,000 Subscription Shares were allotted and issued today by the Company on the terms and subject to the conditions set out in the Subscription Agreement. Following the completion of the Proposed Placement, the issued and paid-up share capital of the Company has increased to 764,899,934 Shares.

The Subscription Shares shall be free from all claims, charges, liens and other encumbrances and shall rank *pari passu* in all respects with and carry all rights similar to the existing Shares.

The Subscription Shares are expected to be listed and quoted on the Catalist board of the SGX-ST on or around 25 July 2022.

By Order of the Board

Lai Kuan Loong, Victor/ Gwendolin Lee Soo Fern
Company Secretaries

21 July 2022

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.